G&W Laboratories names Jay Galeota as president, COO
Prior to joining G&W Laboratories Mr. Galeota spent 28 years at Merck, where he served in many diverse positions across commercial operations, business development, strategy, and innovation, both globally and in the U.S. Most recently, he was Chief Strategy & Business Development Officer and President, Emerging Businesses at Merck.
Prior to that he was President of Hospital & Specialty Care.
Previously, he served as Senior Vice President of Global Human Health Strategy and Business Development, where he helped establish Merck's Global Health Innovation Fund and the Innovative Venture Group to incubate businesses that broadened the company’s portfolio and established leadership in key therapeutic areas and markets.
Mr. Galeota was instrumental in bringing Merck into diabetes and led the team that developed and launched Merck’s top grossing products, Januvia and Janumet. After the merger of Merck and Schering-Plough in 2009, he led the integration of the global pharmaceutical and vaccine businesses.
He started his career in Merck’s commercial organization, where he held various U.S. and global leadership positions and led numerous brands and key product launches across a variety of therapeutic areas.
G&W’s current President, Kurt Orlofski, will assume the newly-created role of President of Generics, where he will lead sales, marketing and commercialization of current and near-term generic products. ■
LATEST MOVES FROM New Jersey
- Campbell Soup Company appoints Fabiola R. Arredondo to board
- Eagle Pharmaceuticals names Richard A. Edlin to board
- Tom Gebhardt chairman and CEO of Panasonic Corp. of North America
- Celgene Corporation COO Jacqualyn Fouse to retire
- Innophos appoints Kim Ann Mink as chairman of the board
More inside POST
Overcome quiet nature and passive approach Leadership